Avastin (Renal Cell Carcinoma) ' Analysis and Forecasts to 2020

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Avastin (Renal Cell Carcinoma) ' Analysis and Forecasts to 2020
Published on October 2011

Report Summary


Summary

GlobalData's pharmaceuticals report, 'Avastin (Renal Cell Carcinoma)- Analysis and Forecasts to 2020' provides Avastin sales
forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales,
competitive landscape, and analysis of sales performance during the forecast period (2008-2020). The report also includes
information on Renal Cell Carcinoma market. This report is built using data and information sourced from GlobalData's proprietary
databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured
press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's
team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Avastin including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Avastin including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2008-2020 for Avastin in each of the seven major markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Content

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 4

Avastin (Renal Cell Carcinoma) ' Analysis and Forecasts to 2020 (From Slideshare) Page 1/6


2.1 RCC Market 4
2.2 Epidemiology 4
2.3 Etiology 6
2.3.1 Tobacco 6
2.3.2 Obesity 6
2.3.3 Acquired Cystic Disease 6
2.3.4 Hypertension 6
2.4 GlobalData Pipeline Report Guidance 7
3 RCC Disease: Market Characterization 8
3.1 RCC Disease Market 8
3.2 RCC Disease Market Forecasts and CAGR 8
3.3 Drivers for the RCC Disease Market 9
3.3.1 High Incidence 9
3.3.2 High Prevalence 10
3.3.3 Emergence of Targeted Therapies 10
3.3.4 Large Unmet Need 10
4 Tumor-Node-Metastases (TNM) Classification of RCC 11
5 Avastin (Bevacizumab) 14
5.1 Introduction 14
5.2 Mechanism of Action 14
5.3 Clinical Studies 14
5.4 Approval History of Avastin 15
5.5 Factors Affecting Sales of Avastin 15
5.5.1 Renal Cancer Market 15
5.5.2 High Efficacy 16
5.5.3 Approval for Second-line Treatment 16
5.5.4 Wide Acceptance 16
5.5.5 Lack of Approval in Japan 16
5.6 Drug Risk Benefit Score 16
5.6.1 Efficacy 16
5.6.2 Safety 17
5.6.3 Compliance 17
5.6.4 Dosing Convenience 17
5.7 Intensity of Competition 17
5.8 Sales forecast 17
5.8.1 Target patient Pool of Avastin 17
5.8.2 Dosing 19
5.8.3 Market Penetration 19
5.8.4 Annual Cost of Therapy 19
5.8.5 Sales Projections of Avastin 19
6 Renal Cell Carcinoma (RCC) Market: Appendix 27
6.1 Market Definitions 27
6.2 Abbreviations 27
6.3 Research Methodology 27
6.3.1 Coverage 28
6.3.2 Secondary Research 28
6.3.3 Forecasting 28
6.3.4 Number of Patients Approved to take the Drug 29



6.3.5 Net Penetration of Drug 29
6.3.6 Net Annual Dosing 30
6.3.7 Annual Cost of Therapy 30
6.3.8 Primary Research 30
6.3.9 Expert Panels 30
6.4 Contact Us 31
6.5 Disclaimer 31
6.6 Sources 31

1.1 List of Tables

Table 1: RCC, Incidences and Mortality, 2008'2030 5
Table 2: RCC, Global, Market Size Forecast ($bn), 2009'2020 8
Table 3: Approval History of Avastin 15
Table 4: Drug Risk Benefit Score of Avastin 16
Table 5: Avastin, RCC, The US and EU'5, Sales Forecast ($m), 2008'2020 20
Table 6: Avastin, RCC, The US, Sales Forecast ($m), 2009'2020 21
Table 7: Avastin, RCC, The UK, Sales Forecast ($m), 2008'2020 22
Table 8: Avastin, RCC, France, Sales Forecast ($m), 2008'2020 23
Table 9: Avastin, RCC, Germany, Sales Forecast ($m), 2008'2020 24
Table 10: Avastin, RCC, Italy, Sales Forecast ($m), 2008'2020 25
Table 11: Avastin, RCC, Spain, Sales Forecast ($m), 2008'2020 26

1.2 List of Figures

Figure 1: Percentage Distribution of Top 20 Cancers, Based on Global Incidence, 2008 4
Figure 2: Difference Between Percentage Distribution of Incidence and Mortality of Top 20 Cancers, 2008 5
Figure 3: Per Capita Cigarette Consumption, The US, 1976-2006 7
Figure 4: RCC, Global, Market Size Forecast ($bn), 2009'2020 8
Figure 5: Oncology, Global, Incidence (in million), 2008-2030 9
Figure 6: RCC, Global, Incidence (in million), 2008-2030 10
Figure 7: Broad Classification of RCC 11
Figure 8: Detailed TNM Classification 12
Figure 9: Classification of RCC (The US, EU except The UK and Japan) 13
Figure 10: Classification of RCC (The UK) 13
Figure 11: Phase III Results, Avastin Vs Placebo 15
Figure 12: Drug Model Diagram of Avastin in the US and EU 18
Figure 13: Drug Model Diagram of Avastin in the UK 18
Figure 14: Avastin, RCC, The US and EU'5, Sales Forecast ($m), 2008'2020 20
Figure 15: Avastin, RCC, Sales Distribution, 2020 20
Figure 16: Avastin, RCC, The US, Sales Forecast ($m), 2009'2020 21
Figure 17: Avastin, RCC, The UK, Sales Forecast ($m), 2008'2020 22
Figure 18: Avastin, RCC, France, Sales Forecast ($m), 2008'2020 23
Figure 19: Avastin, RCC, Germany, Sales Forecast ($m), 2008'2020 24
Figure 20: Avastin, RCC, Italy, Sales Forecast ($m), 2008'2020 25
Figure 21: Avastin, RCC, Spain, Sales Forecast ($m), 2008'2020 26
Figure 22: GlobalData Methodology 27
Figure 23: Drug Model Diagram 29



Figure 24: Patients Approved for the Drug 30


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Avastin (Renal Cell Carcinoma) ' Analysis and Forecasts to 2020

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Avastin (Renal Cell Carcinoma) ' Analysis and Forecasts to 2020